Conversion to Advagraf
PreclinicalSmall molecule
Conversion to Advagraf is one of 31 small molecule programs targeting Kidney Transplant. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbPreclinical
Medrol
PfizerPreclinical
Zemplar
AbbViePreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Cysteine Hydrochloride
NovartisPreclinical
Radicava
ShionogiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conversion to Advagraf. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of British Columbia